Published in Clin Cancer Res on October 15, 2004
Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. Br J Cancer (2009) 1.37
Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol (2006) 1.31
Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer (2008) 1.30
VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway. PLoS One (2009) 1.28
Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer. Br J Cancer (2011) 1.18
Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer. PLoS One (2011) 1.12
Reprogramming of the microRNA transcriptome mediates resistance to rapamycin. J Biol Chem (2013) 1.06
Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung. Clin Cancer Res (2008) 1.03
AKT kinase pathway: a leading target in cancer research. ScientificWorldJournal (2013) 1.01
Response to gefitinib and erlotinib in Non-small cell lung cancer: a restrospective study. BMC Cancer (2009) 1.01
Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma. Clin Cancer Res (2012) 1.00
Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. Cancer Biol Ther (2013) 0.97
Depletion of tumor-associated macrophages slows the growth of chemically induced mouse lung adenocarcinomas. Front Immunol (2014) 0.94
Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer. Carcinogenesis (2013) 0.93
Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors. Curr Opin Oncol (2012) 0.90
Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients. Br J Cancer (2008) 0.90
Vapor of volatile oils from Litsea cubeba seed induces apoptosis and causes cell cycle arrest in lung cancer cells. PLoS One (2012) 0.90
Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor. PLoS One (2013) 0.89
Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer. Transl Lung Cancer Res (2015) 0.89
Regulation of nuclear-cytoplasmic shuttling and function of Family with sequence similarity 13, member A (Fam13a), by B56-containing PP2As and Akt. Mol Biol Cell (2015) 0.84
Stimulation of neoplastic mouse lung cell proliferation by alveolar macrophage-derived, insulin-like growth factor-1 can be blocked by inhibiting MEK and PI3K activation. Mol Cancer (2011) 0.84
Identification of a subset of human non-small cell lung cancer patients with high PI3Kβ and low PTEN expression, more prevalent in squamous cell carcinoma. Clin Cancer Res (2013) 0.84
Clinicopathological correlations of mTOR and pAkt expression in non-small cell lung cancer. Virchows Arch (2012) 0.83
High PHLPP expression is associated with better prognosis in patients with resected lung adenocarcinoma. BMC Cancer (2015) 0.82
Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. Oncotarget (2016) 0.81
β-cryptoxanthin restores nicotine-reduced lung SIRT1 to normal levels and inhibits nicotine-promoted lung tumorigenesis and emphysema in A/J mice. Cancer Prev Res (Phila) (2012) 0.81
The Biological Role of PI3K Pathway in Lung Cancer. Pharmaceuticals (Basel) (2012) 0.81
Antineoplastic effects of mammalian target of rapamycine inhibitors. World J Transplant (2012) 0.80
Down-regulation of Gab1 inhibits cell proliferation and migration in hilar cholangiocarcinoma. PLoS One (2013) 0.80
Multiple roles and therapeutic implications of Akt signaling in cancer. Onco Targets Ther (2009) 0.80
Hypoxia-induced modulation of PTEN activity and EMT phenotypes in lung cancers. Cancer Cell Int (2016) 0.79
Non-small cell lung carcinoma therapy using mTOR-siRNA. Int J Clin Exp Pathol (2012) 0.79
The prognostic value of phosphorylated AKT expression in non-small cell lung cancer: a meta-analysis. PLoS One (2013) 0.79
Involvement of TGFβ-induced phosphorylation of the PTEN C-terminus on TGFβ-induced acquisition of malignant phenotypes in lung cancer cells. PLoS One (2013) 0.79
Unique roles of Akt1 and Akt2 in IGF-IR mediated lung tumorigenesis. Oncotarget (2016) 0.78
p-AKT overexpression in primary renal cell carcinomas and their metastases. Clin Exp Metastasis (2010) 0.78
A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin. Invest New Drugs (2015) 0.78
Correlation between the protein expression of A-kinase anchor protein 95, cyclin D3 and AKT and pathological indicators in lung cancer tissues. Exp Ther Med (2015) 0.77
Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize NSCLC cells to cisplatin. Cancer Gene Ther (2014) 0.76
Expression and clinical significance of the phosphatidylinositol 3-kinase/protein kinase B signal transduction pathway in non-small cell lung carcinoma. Oncol Lett (2014) 0.75
Platycodin D potentiates proliferation inhibition and apoptosis induction upon AKT inhibition via feedback blockade in non-small cell lung cancer cells. Sci Rep (2016) 0.75
AKT expression is associated with degree of pathologic response in adenocarcinoma of the esophagus treated with neoadjuvant therapy. J Gastrointest Oncol (2016) 0.75
Targeting the Mammalian Target of Rapamycin in Lung Cancer. Am J Med Sci (2016) 0.75
ARD1-mediated aurora kinase A acetylation promotes cell proliferation and migration. Oncotarget (2017) 0.75
Toxicological effects of NCKU-21, a phenanthrene derivative, on cell growth and migration of A549 and CL1-5 human lung adenocarcinoma cells. PLoS One (2017) 0.75
Epigallocatechin-3-gallate augments the therapeutic effects of benzo[a]pyrene-mediated lung carcinogenesis. Biofactors (2017) 0.75
Antitumor effect of BPR-DC-2, a novel synthetic cyclic cyanoguanidine derivative, involving the inhibition of MDR-1 expression and down-regulation of p-AKT and PARP-1 in lung cancer. Invest New Drugs (2009) 0.75
High PHLPP1 expression levels predicts longer time of acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma. Oncotarget (2017) 0.75
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol (2007) 5.79
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol (2008) 5.11
Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest (2005) 3.51
Inhaled carbon nanotubes reach the subpleural tissue in mice. Nat Nanotechnol (2009) 2.78
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol (2009) 2.73
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc (2011) 2.39
Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2006) 1.83
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol (2013) 1.75
Tumor necrosis factor-alpha induces transforming growth factor-beta1 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway. Am J Respir Cell Mol Biol (2005) 1.36
Successful bronchoscopic balloon dilation of nonmalignant tracheobronchial obstruction without fluoroscopy. Chest (2004) 1.35
The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J Thorac Oncol (2008) 1.34
Knowns and unknowns of the alveolus. Proc Am Thorac Soc (2008) 1.31
Mesenchymal stem cells produce Wnt isoforms and TGF-beta1 that mediate proliferation and procollagen expression by lung fibroblasts. Am J Physiol Lung Cell Mol Physiol (2009) 1.30
TNF-alpha induces TGF-beta1 expression in lung fibroblasts at the transcriptional level via AP-1 activation. J Cell Mol Med (2009) 1.29
Engraftment of bone marrow progenitor cells in a rat model of asbestos-induced pulmonary fibrosis. Am J Respir Crit Care Med (2007) 1.28
Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res (2011) 1.25
Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF-kappaB and AP-1. Am J Physiol Lung Cell Mol Physiol (2002) 1.25
Susceptibility to asbestos-induced and transforming growth factor-beta1-induced fibroproliferative lung disease in two strains of mice. Am J Respir Cell Mol Biol (2002) 1.19
Characteristics and outcomes of small cell lung cancer patients diagnosed during two lung cancer computed tomographic screening programs in heavy smokers. J Thorac Oncol (2011) 1.17
Polymorphisms in the promoter region of the neutrophil elastase gene are associated with lung cancer development. Clin Cancer Res (2002) 1.17
Pathogenesis of pleural fibrosis. Respirology (2004) 1.16
Asbestos-derived reactive oxygen species activate TGF-beta1. Lab Invest (2004) 1.14
Components necessary for high-quality lung cancer screening: American College of Chest Physicians and American Thoracic Society Policy Statement. Chest (2015) 1.11
Chronic treatment in vivo with β-adrenoceptor agonists induces dysfunction of airway β(2) -adrenoceptors and exacerbates lung inflammation in mice. Br J Pharmacol (2012) 1.06
Resident cellular components of the human lung: current knowledge and goals for research on cell phenotyping and function. Proc Am Thorac Soc (2008) 1.02
A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. J Thorac Oncol (2012) 1.01
Genetic determinants of lung cancer short-term survival: the role of glutathione-related genes. Lung Cancer (2002) 0.93
The latent form of TGFbeta(1) is induced by TNFalpha through an ERK specific pathway and is activated by asbestos-derived reactive oxygen species in vitro and in vivo. J Immunotoxicol (2008) 0.93
Activation of transcription factor IL-6 (NF-IL-6) and nuclear factor-kappaB (NF-kappaB) by lipid ozonation products is crucial to interleukin-8 gene expression in human airway epithelial cells. Environ Toxicol (2007) 0.91
Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. J Thorac Oncol (2006) 0.91
Silica-induced apoptosis in murine macrophage: involvement of tumor necrosis factor-alpha and nuclear factor-kappaB activation. Am J Respir Cell Mol Biol (2002) 0.90
Bleomycin sensitivity of mice expressing dominant-negative p53 in the lung epithelium. Am J Respir Crit Care Med (2002) 0.90
RiboVision suite for visualization and analysis of ribosomes. Faraday Discuss (2014) 0.90
Characterization of side population cells in human malignant mesothelioma cell lines. Lung Cancer (2010) 0.90
Titration of non-replicating adenovirus as a vector for transducing active TGF-beta1 gene expression causing inflammation and fibrogenesis in the lungs of C57BL/6 mice. Int J Exp Pathol (2002) 0.89
Critical acral ischaemia leading to multiple finger amputation: side-effect of long-term (>30 cycles) pemetrexed maintenance treatment in a patient. Br J Clin Pharmacol (2014) 0.89
Mesenchymal stem cells require MARCKS protein for directed chemotaxis in vitro. Am J Respir Cell Mol Biol (2010) 0.87
Flow cytometric enrichment for respiratory epithelial cells in sputum. Cytometry A (2004) 0.85
Gene expression profiling in mouse lung following polymeric hexamethylene diisocyanate exposure. Toxicol Appl Pharmacol (2004) 0.84
Mental health issues in fetal alcohol spectrum disorder. J Ment Health (2011) 0.84
Development of lung tumors in mutant p53-expressing mice after inhalation exposure to asbestos. Chest (2004) 0.83
Laser capture microdissection reveals dose-response of gene expression in situ consequent to asbestos exposure. Int J Exp Pathol (2007) 0.82
Phosphorylation of tumor necrosis factor receptor 1 (p55) protects macrophages from silica-induced apoptosis. J Biol Chem (2003) 0.82
Pharmacoeconomic evaluation of COPD. 2000. Chest (2009) 0.79
Evaluating polycyclic aromatic hydrocarbons using a yeast bioassay. Environ Toxicol Chem (2007) 0.79
Asbestos and lung disease. Am J Respir Cell Mol Biol (2010) 0.78
Workshop on lung disease and the environment: where do we go from here? Am J Respir Crit Care Med (2003) 0.77
Pulmonary toxicity of polymeric hexamethylene diisocyanate aerosols in mice. Toxicol Appl Pharmacol (2003) 0.77
Evaluation of reproductive development following intravenous and oral exposure to DEHP in male neonatal rats. Int J Toxicol (2003) 0.77
Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies. Invest New Drugs (2013) 0.77
Progress in the development of volatile exhaled breath signatures of lung cancer. Ann Am Thorac Soc (2015) 0.76
A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer. Cancer Invest (2006) 0.75
Formoterol and ipratropium in COPD. Am J Respir Crit Care Med (2003) 0.75
Randomized phase II trial of sulindac for lung cancer chemoprevention. Lung Cancer (2012) 0.75
The brush cell. Am J Respir Crit Care Med (2005) 0.75
In memoriam: Bernard (Bernie) A. Shoor. Cytometry A (2016) 0.75
Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Chest (2004) 0.75
The case of the slandered Halloween cupcake: survival after massive pediatric procainamide overdose. Pediatr Emerg Care (2002) 0.75
An HDI polyisocyanate aerosol exposure system for large-scale animal experiments. AIHA J (Fairfax, Va) (2003) 0.75